Jordi Mones, MD, PhD, is scheduled to present the first direct-to-Phase 2 randomized, controlled trial findings for sonpiretigene isteparvovec in macular degeneration on October 4. This presentation follows the release of four-year extension data from the RESTORE trial, which will be detailed by Benjamin Bakall, MD, PhD, on October 1. The data aims to demonstrate the lasting visual improvements provided by the MCO-010 therapy in patients suffering from retinitis pigmentosa.
Nanoscope Therapeutics to Unveil Optogenetic Clinical Data in Vienna
Nanoscope Therapeutics is set to showcase new clinical milestones for its optogenetic pipeline at the 26th Euretina Congress and the Ophthalmology Futures Forums in Vienna. The company will present long-term durability results for retinitis pigmentosa and initial randomized data regarding macular degeneration treatment starting September 30, 2026.
Beyond the clinical findings, Nanoscope leadership will engage with the broader ophthalmology community at the Retina Forum 2026. Samarendra Mohanty, the company’s co-founder and chief scientific officer, will deliver a corporate presentation on September 30. Later that evening, Chief Medical Officer Samuel Barone will participate in a panel discussion focusing on the evolution of therapeutics for geographic atrophy and intermediate age-related macular degeneration. These appearances coincide with the company’s recent regulatory progress, specifically the FDA’s acceptance of the Biologics License Application for MOGENRY.
Comments (0)
No comments yet. Be the first!